A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis

ID: NCT03151551
Status: Recruiting
Phase: Phase 4
Start Date: August 24, 2017
First Submitted: May 04, 2017
Last Updated: February 22, 2018
Results: N/A
Organization: Eli Lilly and Company
Sponsors & Collaborators: Eli Lilly and Company
Location: Argentina, Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Hungary, India, Israel, Italy, Mexico, Netherlands, Poland, South Africa, Spain, Sweden, Switzerland, Ukraine, United Kingdom
Conditions: Psoriatic Arthritis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Study Description

Brief Summary

The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drugs (DMARD) naive.

Detailed Description

Condition or disease Intervention/treatment Phase

Psoriatic Arthritis

Drug: Ixekizumab
Other Names
LY2439821
Drug: Adalimumab
Other Names
Phase 4

Tracking Information

First Submitted DateMay 04, 2017
Last Update Posted DateFebruary 22, 2018
Actual Start DateAugust 24, 2017
Anticipated Completion DateMay 17, 2019
Actual Primary Completion DateNovember 01, 2018
Results First Submitted DateN/A
Received Results Disposit DateN/A

Current Primary Outcome Measures

  • Proportion of Participants Simultaneously Achieving American College of Rheumatology (ACR)50 and Psoriasis Area and Severity Index (PASI)100 [Time Frame: Week 24]

    Proportion of participants simultaneously achieving ACR50 and PASI100 will be derived from the number of participants who have achieved PASI100 and achieved ACR50 divided by the total number of participants.

Original Primary Outcome Measures

Not Available

Current Secondary Outcome Measures

  • Proportion of Participants Achieving ACR50 [Time Frame: Week 24]

    ACR50 response is defined as a ≥50% improvement from baseline for tender joint count (TJC) and swollen joint count (SJC) and in at least 3 of the following 5 criteria: Participant's assessment of joint pain Visual Analog Scale (VAS), Participant's Global Assessment of Disease Activity (PatGA) VAS, Physician's Global Assessment of Disease Activity (PGA) VAS, participant's assessment of physical function using the Health Assessment Questionnaire-Disability Index (HAQ-DI), or High Sensitivity (assay) C-Reactive Protein (hs-CRP).

  • Proportion of Participants Achieving PASI100 [Time Frame: Week 24]

    The PASI is an index that combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 100 are defined as having an improvement of 100% in the PASI score compared to baseline.

  • Change from Baseline in TJC [Time Frame: Baseline, Week 52]

    TJC is determined by examination of 68 joint counts that are assessed for tenderness by pressure and joint manipulation on physical examination.

  • Change from Baseline in SJC [Time Frame: Baseline, Week 52]

    SJC is determined by examination of 66 joint counts that are classified as either swollen or not swollen. Swelling is defined as palpable fluctuating synovitis of the joint.

  • Change from Baseline in Participant's Assessment of Pain VAS [Time Frame: Baseline, Week 52]

    Participants are asked to assess his/her current level of arthritis pain by marking a vertical tick on a horizontal VAS with the left end marked as "no pain" and the right end marked "worst possible pain."

  • Change from Baseline in Participant's Global Assessment of Disease Activity [Time Frame: Baseline, Week 52]

    The participant's overall assessment of his or her PsA activity are recorded using a horizontal VAS.

  • Change from Baseline in Physician's Global Assessment of Disease Activity [Time Frame: Baseline, Week 52]

    The investigator, who must be a physician, is asked to give an overall assessment of the severity of the participant's current PsA activity using a horizontal VAS.

  • Change from Baseline in C-Reactive Protein (CRP) [Time Frame: Baseline, Week 52]

    CRP is the ACR Core Set laboratory measure of acute-phase reactant.

  • Change from Baseline in HAQ-DI [Time Frame: Baseline, Week 52]

    HAQ-DI is a participant reported questionnaire that measures disease-associated disability (physical function). It consists of 24 questions with 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other daily activities. The disability section scores the participant's self-perception on the degree of difficulty (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do), covering the 8 domains. The reported use of special aids or devices and/or the need for assistance of another person to perform these activities is assessed. The HAQ-DI is a composite ranging from 0-3 with lower scores indicating less functional disability.

  • Proportion of Participants Simultaneously Achieving ACR50 and PASI100 [Time Frame: Week 52]

    Proportion of participants simultaneously achieving ACR50 and PASI100 will be derived from the number of participants who have achieved PASI100 and achieved ACR50 divided by the total number of participants.

  • Change from Baseline in Disease Activity Score-CRP (DAS28-CRP) [Time Frame: Baseline, Week 52]

    The DAS28-CRP is a measure of disease activity in 28 joints that consists of a composite numerical score with the following variables: TJC28, SJC28, hs-CRP (measured in milligrams per liter), and Participant's Global Assessment of Disease Activity recorded by participants on a 0 to 100 VAS. For DAS28-CRP, the Tender Joint Count 28 (TJC28) and Swollen Joint Count (SJC28) are a subset of TJC and SJC, and include 14 joints on each side of the body: 2 shoulders, 2 elbows, 2 wrists, 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees.

  • Proportion of Participants Achieving Minimal Disease Activity (MDA) [Time Frame: Week 52]

    MDA is achieved if 5 of 7 outcome measures are fulfilled: TJC ≤1; SJC ≤1; psoriasis activity and severity index (PASI total score) ≤1 or BSA ≤3; participant pain VAS score of ≤15; participant global disease activity VAS score of ≤20; HAQ-DI score ≤0.5; and tender entheseal points ≤1.

  • Proportion of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC) [Time Frame: Week 52]

    The PsARC is a composite criteria reported in terms of the percentage of participants achieving response according to the following criterion: TJC, SJC, PGA, and PatGA. Overall response is defined by improvement from baseline assessment in 2 of 4 criteria, 1 of which must be a joint count; there must not be worsening in any of the 4 criteria: at least 30% reduction in TJC, at least 30% reduction in SJC, at least a 20 millimeter (mm) reduction in PGA and at least a 20 mm reduction in PatGA.

  • Change from Baseline in Modified Composite Psoriatic Disease Activity Index (CPDAI) Score (Modified) [Time Frame: Baseline, Week 52]

    The CPDAI is a validated instrument intended to assess composite psoriatic disease activity and response to therapy. Domains include peripheral arthritis as assessed by the number of tender and swollen joints and the HAQ-DI, skin as assessed by the PASI and the Dermatology Life Quality Index (DLQI), enthesitis as assessed by the number of sites with enthesitis and the HAQ-DI, and dactylitis as assessed by the number of digits affected and the HAQ-DI.

  • Change from Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index in Participants with Enthesitis at Baseline [Time Frame: Baseline, Week 52]

    The SPARCC enthesitis index evaluates tenderness in a total of 16 enthesitis sites: the greater trochanter (right/left [R/L]), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and the supraspinatus insertion (R/L).

  • Change from Baseline in the Leeds Enthesitis Index (LEI) in Participants with Enthesitis at Baseline [Time Frame: Baseline, Week 52]

    The LEI was developed specifically for use in PsA. It measures enthesitis at 6 sites (lateral epicondyle, left and right; medial femoral condyle, left and right; Achilles tendon insertion, left and right).

  • Change from Baseline in the Leeds Dactylitis Index-Basic (LDI-B) in Participants with Dactylitis at Baseline [Time Frame: Baseline, Week 52]

    The LDI-B measures the severity of dactylitis. In each digit, the ratio of the circumference of the affected digit to the circumference of the digit on the opposite hand or foot measured in mm. Each dactylitic digit is defined by a minimum increase of 10% in circumference over the contra-lateral digit.

  • Change from Baseline in Psoriasis Body Surface Area (BSA) [Time Frame: Baseline, Week 52]

    The investigator evaluates the percentage involvement of psoriasis on each participant's BSA on a continuous scale from 0% = no involvement to 100% = full involvement, where 1% corresponded to the size of the participant's handprint including the palm, fingers, and thumb.

  • Change from Baseline in the Nail Psoriasis Severity Index (NAPSI) Fingernails Score in the Subgroup of Participants with Fingernail Involvement at Baseline [Time Frame: Baseline, Week 52]

    The NAPSI scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps by area of involvement. The fingernail is divided into quadrants. Each fingernail is given a score for fingernail bed Ps 0 (none) to 4 (Ps in 4 quadrants of the fingernail) and fingernail matrix Ps 0 (none) to 4 (Ps in 4 quadrants of the matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix Ps in each quadrant. The sum of all fingernails equals the total NAPSI score range is from 0 (no effect) to 80 (more severe psoriasis).

  • Change from Baseline in the Itch NRS [Time Frame: Baseline, Week 52]

    The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from psoriasis is indicated by circling the number that best described the worst level of itching in the past 24 hours.

  • Change from Baseline in Fatigue Severity NRS (Fatigue NRS) Score [Time Frame: Baseline, Week 52]

    The Fatigue Severity NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine." Participants rate their fatigue (weariness, tiredness) by circling the 1 number that described their worst level of fatigue during the past 24 hours.

  • Change From Baseline in Medical Outcomes Study 36-item Short Form Health Survey (SF-36): Physical Component Summary (PCS) [Time Frame: Baseline, Week 52]

    SF-36 is a standardized participant-administered measure designed to evaluate 8 domains of functional health and well-being.

  • Change From Baseline in SF-36: Mental Component Summary (MCS) [Time Frame: Baseline, Week 52]

    SF-36 is a standardized participant-administered measure designed to evaluate 8 domains of functional health and well-being.

  • Change from Baseline in Measures of Health Utility (EuroQol-5 Dimensions 5 Level [EQ-5D 5L]) [Time Frame: Baseline, Week 52]

    The EQ-5D-5L is a standardized measure of health status used to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of 2 components: a descriptive system of the respondent's health and a rating of his/her current health state using a VAS. The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

  • Change from Baseline in Dermatology Life Quality Index (DLQI) Total Score [Time Frame: Baseline, Week 52]

    DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment.

  • Change from Baseline on the Treatment Satisfaction Questionnaire [Time Frame: Baseline, Week 52]

    The Treatment Satisfaction Questionnaire is a clinician-administered questionnaire which provides an assessment of the participant's opinion of the effectiveness, safety, and overall satisfaction of the study medication.

  • Change from Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) [Time Frame: Baseline, Week 52]

    The C-SSRS is a scale that captures the occurrence, severity, and frequency of suicide-related ideations and behaviors during the assessment period.

Original Secondary Outcome Measures

Not Available

Study Design

Brief TitleA Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis
Official TitleA 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive
Brief Summary

The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drugs (DMARD) naive.

Detailed Description

Study TypeInterventional
Study PhasePhase 4
Estimated Enrollment
550
Allocation
Randomized
Interventional Model
Parallel Assignment
Masking
Single
Primary Purpose
Treatment
Conditions
Psoriatic Arthritis
Target Follow-Up Duration N/A
Biospecimen:
N/A
Sampling MethodN/A
Study PopulationN/A
Intervention
Drug: Ixekizumab

Administered SC

Other Names
LY2439821
Drug: Adalimumab

Administered SC

Other Names
Study Groups/Cohorts
Ixekizumab
Ixekizumab given subcutaneously (SC).

Adalimumab
Adalimumab given SC.

Study Arms
Active Comparator Adalimumab
Adalimumab given SC.
Drug : Adalimumab
Administered SC

Experimental Ixekizumab
Ixekizumab given subcutaneously (SC).
Drug : Ixekizumab
Administered SC

Arm Intervention/Treatment
Active Comparator Adalimumab
Adalimumab given SC.
Drug : Adalimumab
Experimental Ixekizumab
Ixekizumab given subcutaneously (SC).
Drug : Ixekizumab

Recruitment Information

Recruitment Status:Recruiting
Enrollment550
Completion DateMay 17, 2019
Eligibility Criteria: Inclusion Criteria:
- Presents with established diagnosis of active psoriatic arthritis for at least 6 months, and currently meets Classification for Psoriatic Arthritis (CASPAR) criteria
- Active PsA defined as the presence of at least 3 tender and at least 3 swollen joints
- Presence of active plaque psoriasis with a BSA ≥3%
- Men must agree to use a reliable method of birth control or remain abstinent during the study
- Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment
- Have had an inadequate response when treated with 1 or more conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)

Exclusion Criteria:
- Current or prior use of biologic agents for treatment of Ps or PsA
- Evidence of active inflammatory arthritic syndromes or spondyloarthropathies other than PsA
- Have participated in any study with interleukin 17 (IL-17) antagonists, including ixekizumab
- Serious disorder or illness other than psoriatic arthritis
- Serious infection within the last 3 months
- Women who are breastfeeding
GenderAll
Age18 Years to N/A
Accepts Healthy VolunteersNo
Contacts
Listed Location Countries
Argentina
Australia
Austria
Belgium
Canada
Denmark
Finland
France
Germany
Hungary
India
Israel
Italy
Mexico
Netherlands
Poland
South Africa
Spain
Sweden
Switzerland
Ukraine
United Kingdom

Administrative Information

NCT Number:NCT03151551
Other Study ID Numbers
16687
I1F-MC-RHCF
2016-004585-25
Has Data Monitoring CommitteeNo
U.S. FDA-regulated Product Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Device Product Not Approved or Cleared by U.S. FDA: No
IPD Sharing Statement
Not Available
Responsible Party,
Study Sponsor
Eli Lilly and Company
Collaborators
Not Available
Investigators
Study Director
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company